Terms: = Germ cell tumor AND ARID2, ENSG00000189079, 196528, Q68CP9, p200, KIAA1557, FLJ30619, DKFZp779P0222, DKFZp686G052, BAF200
21 results:
1. arid2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract] [Full Text] [Related]
2. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma.
Lorenzo-Guerra SL; Codina-Martínez H; Suárez-Fernández L; Cabal VN; García-Marín R; Riobello C; Vivanco B; Blanco-Lorenzo V; Sánchez-Fernández P; López F; Llorente JL; Hermsen MA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201285
[TBL] [Abstract] [Full Text] [Related]
3. Association of the Genomic Profile of Medullary Thyroid Carcinoma with tumor Characteristics and Clinical Outcomes in an International Multicenter Study.
Xu B; Viswanathan K; Ahadi MS; Ahmadi S; Alzumaili B; Bani MA; Baudin E; Behrman DB; Capelletti M; Chau NG; Chiarucci F; Chou A; Clifton-Bligh R; Coluccelli S; de Biase D; De Leo A; Dogan S; Fagin JA; Fuchs TL; Glover AR; Hadoux J; Lacroix L; Lamartina L; Lubin DJ; Luxford C; Magliocca K; Maloberti T; Mohanty AS; Najdawi F; Nigam A; Papachristos AJ; Repaci A; Robinson B; Scoazec JY; Shi Q; Sidhu S; Solaroli E; Sywak M; Tuttle RM; Untch B; Barletta JA; Al Ghuzlan A; Gill AJ; Ghossein R; Tallini G; Ganly I
Thyroid; 2024 Feb; 34(2):167-176. PubMed ID: 37842841
[No Abstract] [Full Text] [Related]
4. Assessing the genetic risk of nodular melanoma using a candidate gene approach.
Stark MS; Sturm RA; Pan Y; Smit DJ; Kommajosyula V; Lee KJ; Jagirdar K; McLean C; Duffy DL; Soyer HP; Mar VJ
Br J Dermatol; 2024 Jan; 190(2):199-206. PubMed ID: 37766469
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
[TBL] [Abstract] [Full Text] [Related]
6. Whole-exome sequencing reveals genetic variants in low-risk and high-risk neuroblastoma.
Altun Z; Yuan H; Baran B; Aktaş S; Sönmez EE; Küçük C; Olgun N
Gene; 2023 Apr; 860():147233. PubMed ID: 36736507
[TBL] [Abstract] [Full Text] [Related]
7. Next-generation Sequencing as a Potential Diagnostic Adjunct in Distinguishing Between Desmoplastic Melanocytic Neoplasms.
Roth A; Boutko A; Lampley N; Dhillon S; Hagstrom M; Olivares S; Dittman D; Jennings L; Santana Dos Santos L; Busam K; Gerami P
Am J Surg Pathol; 2023 Mar; 47(3):318-325. PubMed ID: 36383901
[TBL] [Abstract] [Full Text] [Related]
8. Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study.
Luo L; Shen R; Arora A; Orlow I; Busam KJ; Lezcano C; Lee TK; Hernando E; Gorlov I; Amos C; Ernstoff MS; Seshan VE; Cust AE; Wilmott J; Scolyer RA; Mann G; Nagore E; Funchain P; Ko J; Ngo P; Edmiston SN; Conway K; Googe PB; Ollila D; Lee JE; Fang S; Rees JR; Thompson CL; Gerstenblith M; Bosenberg M; Gould Rothberg B; Osman I; Saenger Y; Reynolds AZ; Schwartz M; Boyce T; Holmen S; Brunsgaard E; Bogner P; Kuan PF; Wiggins C; Thomas NE; Begg CB; Berwick M;
Pigment Cell Melanoma Res; 2022 Nov; 35(6):605-612. PubMed ID: 35876628
[TBL] [Abstract] [Full Text] [Related]
9. Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma.
Carcamo S; Nguyen CB; Grossi E; Filipescu D; Alpsoy A; Dhiman A; Sun D; Narang S; Imig J; Martin TC; Parsons R; Aifantis I; Tsirigos A; Aguirre-Ghiso JA; Dykhuizen EC; Hasson D; Bernstein E
Cell Rep; 2022 Apr; 39(1):110637. PubMed ID: 35385731
[TBL] [Abstract] [Full Text] [Related]
10. arid2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma.
Fukumoto T; Lin J; Fatkhutdinov N; Liu P; Somasundaram R; Herlyn M; Zhang R; Nishigori C
J Invest Dermatol; 2021 Jun; 141(6):1564-1572.e4. PubMed ID: 33333124
[TBL] [Abstract] [Full Text] [Related]
11. Presence and prevalence of UV related genetic mutations in uveal melanoma: similarities with cutaneous melanoma.
Goh AY; Ramlogan-Steel CA; Jenkins KS; Steel JC; Layton CJ
Neoplasma; 2020 Sep; 67(5):958-971. PubMed ID: 32305056
[TBL] [Abstract] [Full Text] [Related]
12. Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles.
Williams EA; Shah N; Montesion M; Sharaf R; Pavlick DC; Sokol ES; Alexander BM; Venstrom JM; Elvin JA; Ross JS; Tse JY; Mochel MC
Mod Pathol; 2020 Aug; 33(8):1466-1474. PubMed ID: 32123303
[TBL] [Abstract] [Full Text] [Related]
13. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.
Li H; Yang F; Hu A; Wang X; Fang E; Chen Y; Li D; Song H; Wang J; Guo Y; Liu Y; Li H; Huang K; Zheng L; Tong Q
EMBO Mol Med; 2019 Dec; 11(12):e10835. PubMed ID: 31709724
[TBL] [Abstract] [Full Text] [Related]
14. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas.
Johncilla M; Stachler M; Misdraji J; Lisovsky M; Yozu M; Lindeman N; Lauwers GY; Odze RD; Srivastava A
Mod Pathol; 2018 Jun; 31(6):989-996. PubMed ID: 29422640
[TBL] [Abstract] [Full Text] [Related]
15. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Pan D; Kobayashi A; Jiang P; Ferrari de Andrade L; Tay RE; Luoma AM; Tsoucas D; Qiu X; Lim K; Rao P; Long HW; Yuan GC; Doench J; Brown M; Liu XS; Wucherpfennig KW
Science; 2018 Feb; 359(6377):770-775. PubMed ID: 29301958
[TBL] [Abstract] [Full Text] [Related]
16. Precision medicine driven by cancer systems biology.
Filipp FV
Cancer Metastasis Rev; 2017 Mar; 36(1):91-108. PubMed ID: 28265786
[TBL] [Abstract] [Full Text] [Related]
17. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
Kunz M; Hölzel M
Cancer Metastasis Rev; 2017 Mar; 36(1):53-75. PubMed ID: 28210865
[TBL] [Abstract] [Full Text] [Related]
18. Clonal architectures and driver mutations in metastatic melanomas.
Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
[TBL] [Abstract] [Full Text] [Related]
19. Biallelic germline and somatic mutations in malignant mesothelioma: multiple mutations in transcription regulators including mSWI/SNF genes.
Yoshikawa Y; Sato A; Tsujimura T; Otsuki T; Fukuoka K; Hasegawa S; Nakano T; Hashimoto-Tamaoki T
Int J Cancer; 2015 Feb; 136(3):560-71. PubMed ID: 24916674
[TBL] [Abstract] [Full Text] [Related]
20. A landscape of driver mutations in melanoma.
Hodis E; Watson IR; Kryukov GV; Arold ST; Imielinski M; Theurillat JP; Nickerson E; Auclair D; Li L; Place C; Dicara D; Ramos AH; Lawrence MS; Cibulskis K; Sivachenko A; Voet D; Saksena G; Stransky N; Onofrio RC; Winckler W; Ardlie K; Wagle N; Wargo J; Chong K; Morton DL; Stemke-Hale K; Chen G; Noble M; Meyerson M; Ladbury JE; Davies MA; Gershenwald JE; Wagner SN; Hoon DS; Schadendorf D; Lander ES; Gabriel SB; Getz G; Garraway LA; Chin L
Cell; 2012 Jul; 150(2):251-63. PubMed ID: 22817889
[TBL] [Abstract] [Full Text] [Related]
[Next]
